Effect of naive and radiolabeled rhTRAIL on the cervical cancer xenografts in mice

• Published in: Therapeutic delivery Vol. 5; no. 2; p. 139
• Main Authors: Wang, Xing Guo, Jandl, Thomas, Dadachova, Ekaterina, Revskaya, Ekaterina
• Format: Journal Article
• Language: English
• Published: England 01.02.2014
• Subjects: Animals; Antineoplastic Agents - metabolism; Antineoplastic Agents - pharmacology; Apoptosis - drug effects; Cell Line, Tumor; Cell Survival - drug effects; Dose-Response Relationship, Drug; Female; Humans; Inhibitory Concentration 50; Iodine Radioisotopes; Mice; Mice, Inbred BALB C; Mice, Nude; Radioisotopes; Recombinant Proteins - pharmacology; Rhenium; Time Factors; Tissue Distribution; TNF-Related Apoptosis-Inducing Ligand - metabolism; TNF-Related Apoptosis-Inducing Ligand - pharmacology; Tumor Burden - drug effects; Uterine Cervical Neoplasms - drug therapy; Uterine Cervical Neoplasms - metabolism; Uterine Cervical Neoplasms - pathology; Xenograft Model Antitumor Assays
• ISSN: 2041-5990
• DOI: 10.4155/TDE.13.137

There is a need for novel treatments of advanced cervical cancer. We investigated the utility of recombinant human TNF-related apoptosis-inducing ligand (rhTRAIL), a molecule capable of inducing apoptosis in cancer cells, for the therapy of CasKi cervical cancer xenografts in nude mice. CasKi cells proved to be sensitive in vitro to rhTRAIL with an IC50 of 120 ng/ml. (125)I-tagged rhTRAIL specifically accumulated in CasKi tumors in mice with the highest uptake of 9.4% ID/g at 2 h post-injection. Both naive and 200 µCi (188)Re-tagged rhTRAIL administered in the amount of 0.35 mg/kg body weight significantly retarded CasKi tumor growth to the same extent in mice without the side effects of cisplatin chemotherapeutic control. rhTRAIL is a promising novel agent for treatment of advanced cervical cancer.